Analysis of WHO-based Prognostic Scoring System (WPSS) of myelody-splastic syndrome and its comparison with international prognostic scoring system (IPSS) in 100 Chinese patients

Chinese Journal of Cancer Research

Volumn 21, Issue 1, 2009, Pages 50-55

  Wei, Jia ^a   Zhou, Xiao Fen ^a   Zhou, Jian Feng ^a   Chen, Yan ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

IPSS; Prognosis; RBC transfusion dependency; Time dependent; WPSS

Indexed keywords

ADULT; AGED; ARTICLE; CHROMOSOME ANALYSIS; CYTOPENIA; ERYTHROCYTE TRANSFUSION; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; NEUTROPHIL COUNT; OVERALL SURVIVAL; PROGNOSIS; SCORING SYSTEM; SURVIVAL RATE; THROMBOCYTE COUNT; WORLD HEALTH ORGANIZATION BASED PROGNOSTIC SCORING SYSTEM;

EID: 60349083359     PISSN: 10009604     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11670-009-0050-7     Document Type: Article

References (18)

1. Cazzola M, Malcovati L. Myelodysplastic syndromes-Coping with ineffective hematopoiesis [J]. N Engl J Med 2005;352:536-538.
2. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes [J]. Blood 1997;89:2079-2088.
3. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms [J]. Blood 2002;100: 2292-2302.
4. Howe RB, Porwit-MacDonald A, Wanat R, et al. The WHO classification of MDS does make a difference [J]. Blood 2004;103:3265-3270.
5. Breccia M, Carmosino I, Biondo F, et al. Usefulness and prognostic impact on survival of WHO reclassification in FAB low risk myelodyplastic syndromes [J]. Leuk Res 2006;30:178-182.
6. Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: A basis for clinical decision making [J]. J Clin Oncol 2005;23:7594-7603.
7. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes [J]. J Clin Oncol 2007;25:3503-3510.
8. Müller-Berndorff H, Haas PS, Kunzmann R, et al. Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: Results of a single-center analysis [J]. Ann Hematol 2006;85:502-513.
9. Navarro I, Ruiz MA, Cabello A, et al. Classification and scoring systems in myelodysplastic syndromes: A retrospective analysis of 311 patients [J]. Leuk Res 2006;30:971-977.
10. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes [J]. Br J Haematol 1982;51:189-199.
11. ISCN. An International System for Human Cytogenetic Nomenclature. In: Mitelman F, ed. Guidelines for Cancer Cytogenetics [M]. New York: Karger. 1995;1-114.
12. Haus O, Kotlarek-Haus S, Potoczek S, et al. Myelodysplastic syndromes according to FAB and WHO classification. Single center experience [J]. Neoplasma 2006;53:136-143.
13. Bernasconi P, Klersy C, Boni M, et al. Incidence and prognostic significance of karyotype abnormalities in de novo primary myelodysplastic syndromes: A study on 331 patients from a single institution [J]. Leukemia 2005;19:1424-131.
14. Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: Evidence from a core dataset of 2124 patients [J]. Blood 2007;110:4385-4395.
15. Demirkan F, Alacacioglu I, Piskin O, et al. The clinical, haematological and morphological profile of patients with myelodysplastic syndromes: A single institution experience from Turkey [J]. Leuk Lymphoma 2007;48:1372-1378.
16. Cazzola M, Malcovati L. Myelodysplastic syndromes-coping with ineffective hematopoiesis [J]. N Engl J Med 2005;352:536-538.
17. Wells DA, Benesch M, Loken MR, et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation [J]. Blood 2003;102:394-403.
18. Pirruccello SJ, Young KH, Aoun P. Myeloblast phenotypic changes in myelodysplasia. CD34 and CD117 expression abnormalities are common [J]. Am J Clin Pathol 2006; 125:884-894.